Several RNR inhibitors are also used in anti-leukaemia therapies, such as hydroxyurea (HU) that targets RRM2 to treat chronic myeloid leukaemia (CML) and AML and the ribonucleoside analogues cytarabine and clofarabine that target RRM1 to treat acute leukaemia [23,24,25]. The gene discussed is NR2E3; the disease is leukemia.